<DOC>
	<DOCNO>NCT02292277</DOCNO>
	<brief_summary>Patients myocardial infarction , include layer heart 's muscle wall common often receive pharmacological treatment platelet inhibit drug ticagrelor . However , drug uptake oral dose 180mg ticagrelor thoroughly study patient . The present study evaluate ticagrelor uptake platelet aggregation 180 mg load dose ticagrelor patient .</brief_summary>
	<brief_title>Ticagrelor Pharmacokinetics NSTEMI</brief_title>
	<detailed_description>This study consider observational prospective case-controlled study , accord Swedish Medical Product Agency ( MPA ) , response enquiry . This due lack intervention routine medical treatment . Patients non-ST elevation myocardial infarction ( NSTEMI ) common , pharmacokinetic property ticagrelor acute phase , best knowledge , thoroughly studied patient . The present study evaluate ticagrelor uptake platelet aggregation 180 mg load dose ticagrelor NSTEMI patient compare result control group patient stable coronary artery disease . Hypotheses/questions The stress reaction suffer NSTEMI cause delay absorption possibly delay lower maximal plasma concentration load dose ticagrelor thus delay possibly impaired inhibition platelet aggregation . Method Study population Subjects eligible study ticagrelor naïve patient NSTEMI present emergency room Södersjukhuset . Upon arrival emergency room write informed consent obtain patient receive 180 mg load dose ticagrelor responsible physician choses therapy . Inclusion criterion : 1 ) diagnosis NSTEMI ( i.e relevant symptom associate ischemic ECG change ( categorize STEMI ) and/or relevantly increase cardiac marker ) ; 2 ) indication 180 mg ticagrelor load dose . Control group Patients stable coronary artery disease present cardiology clinic Södersjukhuset . A single 180 mg load dose ticagrelor administrate responsible physician choses therapy . Inclusion criterion . The inclusion criterion control group document stable coronary artery disease . Exclusion criterion : 1 ) ACS within last 3 month ; 2 ) Age &lt; 18 year ; 3 ) Administration ticagrelor week inclusion ; 4 ) Treatment glycoprotein IIb/IIIa antagonists within 48 hour inclusion ; 5 ) Ongoing morphine treatment . Study procedures method Samples venous blood collect lithium-heparin tube , centrifuge 1500 g 4ºC 10 min within 30 min blood sample follow time point : pre-dose , 1 , 2 , 3 , 4 , 5 , 6 hour post-dose , show table . For P2Y12-antagonist naïve patient control , sample venous blood Hirudin tube pharmacodynamics evaluation perform analysis use ADP-induced platelet aggregation assay ( Multiplate® , Roche Diagnostics International Ltd , Rotkreuz , Switzerland ) . The result plasma sample store minus 20ºC analyze . Plasma concentration ticagrelor active metabolite AR-C124910XX determine validate method ( high-performance liquid chromatography tandem mass spectrometry detection ; LC-MS/MS ) certify laboratory ( Covance Laboratories Inc. ) . Statistical analysis The median Tmax control group stable coronary artery disease expect approximately 2 hour 180 mg load dose . The range Tmax patient stable coronary artery disease receive 180mg load dose 1 8 hour . A rough standard deviation estimate 1.25 hour obtain range use formula ( ln ( maxT⁡max ) - ln ( minTmax ) ) /k statistical textbook Dixon et al . A statistician estimate k 9.5 natural distribution table . The estimated standard deviation 0.22 logarithm scale calculate use calculation . For study group NSTEMI , large standard deviation expect estimate follow formula provide statistician : sqrt ( ( 0.22^2 ) × 2 ) ) =0.31 . To make sample size calculation possible , calculated standard deviation anti-logged use exponential function find 1.25 hour 1.36 hour , respectively . For power calculation , 50 % delay median ticagrelor Tmax ( 1 hour delay ) consider , regard clinical significant difference . A power calculation describe time Tmax estimate standard deviation , show study 80 % power would require 40 patient study group 20 patient control group .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>A diagnosis NSTEMI ( i.e relevant symptom associate ischemic ECG change ( categorize STEMI ) and/or relevantly increase cardiac marker ) ; An indication 180 mg ticagrelor load dose . Ticagrelor contraindication , include Hypersensitivity active substance excipients list section 6.1 Active pathological bleeding History intracranial haemorrhage Moderate severe hepatic impairment . Coadministration ticagrelor strong CYP3A4 inhibitor ( e.g. , ketoconazole , clarithromycin , nefazodone , ritonavir , atazanavir ) contraindicate , co‑administration may lead substantial increase exposure ticagrelor Age &lt; 18 year Administration ticagrelor week inclusion Treatment glycoprotein IIb/IIIa antagonists within 48 hour inclusion Ongoing morphine treatment . However , patient NSTEMI without morphine treatment rare , exclusion criterion protocol may reevaluate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Platelet Aggregation</keyword>
	<keyword>Platelet Function Tests</keyword>
</DOC>